Industry | 2018.10.17
ERS Genomics and Syngulon Sign License Agreement on CRISPR-Cas9 Genome Editing Patents for Industrial Applications
ERS Genomics Ltd and Syngulon, a synthetic biology startup developing original genetic technologies using bacteriocins, announced today a non-exclusive license agreement which provides Syngulon with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in combination with Syngulon Patent Rights.
(PRWeb October 17, 2018)
Read the full story at https://www.prweb.com/releases/ers_genomics_and_syngulon_sign_license_agreement_on_crispr_cas9_genome_editing_patents_for_industrial_applications/prweb15840777.htm
For more information, please visit
https://www.prweb.com/releases/ers_genom[...]applications/prweb15840777.htm
